GleamWall
中文EN

ENSC Ensysce Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1716947 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY37.9%
TTM net income YoY-729.4%
TTM EPS YoY-18.3%
Revenue 3-yr CAGR25.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,477.0%
Net margin-1,470.4%
FCF margin—
EBITDA margin-1,476.6%

Returns

ROE-635.4%
ROA-533.3%
ROIC (approx.)—
Asset turnover0.36x

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.02x
Interest coverage-7,157.58x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-484.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue$2.18M$1.16M$960,999$1.88M$493,104$1.37M$1.32M$1.30M
R&D expense$3.18M$2.47M$3.35M$3.61M$2.95M$1.92M$1.89M$3.80M
SG&A expense$1.59M$1.27M$1.18M$1.05M$1.28M$1.20M$1.40M$1.08M
Operating income-$82.50M-$2.58M-$3.56M-$2.78M-$3.74M-$1.75M-$1.97M-$3.58M
Interest expense$3,147$320$3,923$5,382$6,369$3,160$3,856$10,753
Net income-$82.11M-$2.57M-$3.56M-$2.77M-$3.73M-$1.73M-$1.95M-$3.56M
EBITDA-$82.49M-$2.57M-$3.56M-$2.78M-$3.74M-$1.75M-$1.97M-$3.58M
EPS (basic)-4.52-0.20-0.52—-1.29-0.79-1.39—
EPS (diluted)-4.52-0.20-0.52—-1.29-0.79-1.39—
Weighted avg. shares (diluted)18.19M13.04M6.84M—2.89M2.20M1.40M—
Balance sheet
Cash & equivalents$29.67M$676,704$745,482$4.31M$1.67M$2.21M$3.05M$3.50M
Current assets$30.80M$2.85M$2.01M$7.25M$2.93M$5.28M$4.40M$5.34M
PP&E, net$156,279$111,063$117,596$124,129$123,643———
Total assets$30.95M$2.96M$2.17M$7.45M$3.18M$5.57M$4.61M$5.60M
Current liabilities$3.84M$4.07M$2.84M$4.57M$2.30M$2.51M$1.76M$2.21M
Total liabilities$3.84M$4.07M$2.84M$4.57M$2.30M$2.51M$1.89M$2.22M
Shareholders' equity$27.44M-$781,697-$340,042$3.21M$1.20M$3.39M$3.05M$3.71M
Shares outstanding19.46M16.23M9.28M4.57M3.18M2.39M1.64M1.36M
Cash flow statement
Operating cash flow-$1.40M-$1.96M-$3.50M-$1.53M-$1.87M-$2.71M-$1.71M-$764,090
Capital expenditure———$0————
Free cash flow———-$1.53M————
Investing cash flow———$0————
Financing cash flow$19.24M$1.89M-$63,947$4.16M$1.45M$1.87M$1.26M$112,575
Depreciation & amortization$6,533$6,533$6,533$6,533$0$0$0$0
Stock-based compensation$405$1,870$8,743$24,339$45,858$90,638$16,251$30,149

Free plan shows the latest 8 periods; Pro shows all 36 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.